Immuron Ltd
IMRN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001660046
No open-market purchases or sales by Immuron Ltd insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $82.2K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 6
- 13F valueReported value at the end of Q2 2026
- $82.2K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding IMRN, Q2 2026
No superinvestor reported holding IMRN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Immuron Ltd insiders from Form 4, newest first.
No open-market purchases or sales by Immuron Ltd insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Immuron Ltd at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 43,123 | $45.7K | 0.00% | +29,319+212.4% | Added |
| HRT Financial LP | 20,584 | $21.0K | 0.00% | +20,584 | New |
| Rhumbline Advisers | 7,367 | $7.81K | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 5,200 | $5.51K | 0.00% | +600+13.0% | Added |
| Morgan Stanley | 1,700 | $1.80K | 0.00% | −28,874−94.4% | Reduced |
| UBS Group AG | 363 | $385 | 0.00% | +363 | New |